Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.

Cardiometabolic profile moderately unfavourable in middle-aged PCOS patients

24 Jan 2020

Middle-aged women with polycystic ovary syndrome (PCOS) exhibit only a moderately unfavourable cardiometabolic profile despite having an increased body mass index (BMI) and waist circumference, as reported in a study.

The cross-sectional study involved 200 PCOS patients and 200 matched controls, and the average age of the overall population was 51 years. Researchers assessed anthropometrics, insulin, lipid levels, prevalence of metabolic syndrome and type II diabetes status. They also calculated 10‐year Framingham risk score, the cardiovascular health score and carotid intima‐media thickness (cIMT).

Compared with controls, PCOS patients were more likely to have increased waist circumference and BMI and were predisposed to hypertension (p<0.001).

There were no significant between-group differences in the prevalence rates of type II diabetes and metabolic syndrome, as well as in lipid levels. However, cIMT was lower in in the PCOS group (p<0.001).

The estimated cardiovascular health and 10‐year cardiovascular disease (CVD) risk were likewise similar in the PCOS and control groups.

Findings of the present study point to a need for long‐term follow‐up of women with PCOS in order to establish the long‐term risk of CVD, the researchers said. “[A]lthough some metabolic disturbances were present in our large cohort of middle‐aged women with PCOS, we found no evidence for premature atherosclerosis or an increased risk for future CVD. Only time will tell whether this will indeed translate into a better cardiovascular health in women with PCOS than was previously anticipated.”

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS JPOG - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Routinely used for treating cardiovascular diseases, statins have been shown to benefit other conditions, and new evidence suggests that using the drug at high intensity reduces the risk of hip or knee replacement, an effect that may be specific to rheumatoid arthritis.
Jairia Dela Cruz, 5 days ago
Following vegan and vegetarian diets, which offer plenty of what is good for health, has been reported to have a downside: an increased risk of depression and anxiety, especially for younger adults.
Pearl Toh, 29 Jun 2020
Having migraine during midlife appears to be associated with a higher risk of developing dementia in later life, according to a large population-based longitudinal Danish study presented at the AHS* 2020 Virtual Meeting, indicating that migraine may be a risk factor for dementia.
Roshini Claire Anthony, 3 days ago

Upadacitinib may be a suitable treatment for patients with active psoriatic arthritis (PsA) who have insufficient response to non-biologic disease-modifying anti-rheumatic drugs (non-bDMARDs), according to results of the phase III SELECT-PsA-1* trial presented at EULAR 2020.